What rate of 3% hypertonic saline should be used in pediatric patients to lower intracranial pressure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Rate of 3% Hypertonic Saline for Lowering ICP in Pediatrics

For pediatric patients with elevated intracranial pressure, administer 3% hypertonic saline as a continuous infusion targeting serum sodium of 145-155 mmol/L, or as bolus doses of 5 mL/kg over 5 minutes to 2 hours when acute ICP reduction is needed. 1

Administration Methods

Continuous Infusion (Preferred for Sustained Control)

  • Target serum sodium: 145-155 mmol/L 1
  • Infusion rates typically range from 0.5-2 mL/kg/hr after initial bolus 2
  • This approach has been safely used for mean duration of 7.6 days in pediatric traumatic brain injury 3
  • Studies demonstrate sustained ICP control without significant adverse effects even with prolonged use 1

Bolus Therapy (For Acute ICP Elevation)

  • Dose: 5 mL/kg of 3% saline 4
  • Administer over 5 minutes to 2 hours 2
  • Expected effect: ICP reduction of approximately 5 mmHg lasting 3 hours 4
  • The "53-53 rule" applies: 5 mL/kg of 3% HTS decreases ICP by at least 5 mmHg for 3 hours 4
  • CPP increases by approximately 4 mmHg within 1 hour 4

Clinical Algorithm

Step 1: Initial Assessment

  • Confirm elevated ICP requiring osmotic therapy
  • Check baseline serum sodium (must be <155 mmol/L before administration) 1

Step 2: Choose Administration Strategy

  • For acute ICP crisis: Bolus 5 mL/kg over 5-30 minutes
  • For sustained ICP control: Initiate continuous infusion at 0.5-1 mL/kg/hr after loading dose

Step 3: Monitoring Protocol

  • Measure serum sodium within 6 hours of bolus administration 1
  • For continuous infusions, monitor sodium every 6-12 hours
  • Do not re-administer until serum sodium <155 mmol/L 1
  • Track ICP and CPP continuously if monitoring available

Safety Profile

The evidence strongly supports safety in pediatric populations:

  • No osmotic demyelination syndrome documented in 68 children receiving 3% infusions, including autopsy and MRI evidence 1
  • Mean highest serum sodium of 170.7 mmol/L tolerated without adverse effects 1, 3
  • Maximum osmolarity of 431 mOsm/L documented in individual patients without complications 1
  • Two cases of acute renal failure occurred concurrent with sepsis/multisystem organ dysfunction, both recovered fully 3

Critical Caveats

Pre-bolus sodium does NOT predict effectiveness: The magnitude of ICP reduction is not correlated with baseline serum sodium concentration 4. This means 3% saline remains effective even at higher baseline sodium levels (though safety monitoring remains essential).

Interhemispheric discordance matters: Patients with bihemispheric or unihemispheric rcSO2 <60% with interhemispheric discordance >10% show the greatest positive response but require more frequent dosing 5.

Therapeutic response timing: Significant 15% improvement in cerebral oxygenation occurs within 1.2-2.1 minutes of infusion, particularly in subdural hematomas 5.

Comparison to Mannitol

Recent high-quality pediatric studies show:

  • 3% HTS superior to 20% mannitol for achieving target ICP <20 mmHg (79.3% vs 53.6%) 6
  • Greater ICP reduction: -14.3 mmHg vs -5.4 mmHg with mannitol 6
  • Higher CPP elevation: 15.4 mmHg vs 6 mmHg 6
  • Shorter mechanical ventilation duration and PICU stay 6

However, the most recent 2025 multicenter cohort study found no difference in mortality or functional outcomes between HTS and mannitol 7, and a 2025 meta-analysis confirmed no significant differences in mortality, ICP changes, or secondary outcomes 8.

Practical Implementation

Route of administration: Both central and peripheral IV access are safe 9. While central access is traditionally preferred, peripheral administration is acceptable with proper monitoring for phlebitis and extravasation 9.

Storage considerations: Institutional protocols should address regulatory requirements for safe storage in patient care areas with appropriate safeguards 9.

The evidence base is Grade A for ICP reduction efficacy but does not demonstrate survival benefit or improved neurological outcomes 1. Use 3% HTS as part of a comprehensive ICP management algorithm, not as monotherapy.

References

Research

Randomized Clinical Trial of 20% Mannitol Versus 3% Hypertonic Saline in Children With Raised Intracranial Pressure Due to Acute CNS Infections.

Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 2020

Research

Therapeutic comparison of hypertonic saline and mannitol in pediatric intracranial hypertension: a systematic review and meta-analysis.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2025

Research

Hypertonic saline use in neurocritical care for treating cerebral edema: A review of optimal formulation, dosing, safety, administration and storage.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.